Under the agreements, MSN Laboratory will establish a manufacturing unit along with a Research & Development (R&D) center. Laurus Labs and Aurobindo Pharma will set up formulation units. Gland Pharma has shown interest in opening an R&D center, as well as manufacturing units for injectables and drug substances. Dr. Reddy's Labs plans to establish a unit for injectables and biosimilars. Hetero Labs will set up a plant for finished dose and injectable manufacturing.
Thanking the MSN Group for the noble gesture, Yagneshwara Prabhu said that the Akshaya Patra Foundation is serving mid-day meals to two-million children every school day across the country.
Dr Reddy's Laboratories reduced the price of its cardiovascular drug Cidmus, MSN Group, launched the world’s first generic Palbociclib tablets for advanced breast cancer therapy
Hyderabad: Three pharma companies from Hyderabad have entered into agreement with UN-backed Medicines Patent Pool (MPP), headquartered in Geneva, to manufacture and supply a generic version of Pfizer’s Covid-19 oral treatment Nirmatrelvir. Aurobindo Pharma said it signed a sub-license agreement with MPP. Earlier, MPP signed voluntary licensing agreement with Pfizer for sub-licensing this Covid-19 treatment […]
Hyderabad: MSN Group, a Hyderabad-based pharma company, is all set to launch the generic molnupiravir 200 mg capsules for treating Covid-19 under the brand name Moluflow. Molnupiravir is an oral Covid-19 antiviral medicine indicated for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk […]
Hyderabad: Hyderabad-based MSN Labs has launched anti-epileptic drug, India’s first generic vigabatrin powder for oral solution under the brand name Viganext. An infantile spasm is a seizure with sudden stiffening of the body and brief bending forward or backward of the arms, legs and head. Vigabatrin is recommended as the first-line therapy for infantile spasm, […]
